November 13, 2015
November 04, 2015
CASI Pharmaceuticals CEO Ken K. Ren, PhD rang the closing bell at NASDAQ on Thursday, June 11, 2015 4PM. Click the link below to access NASDAQ’s video archive to view the ceremony. http://www.nasdaq.com/marketsite/marketsite-events-detail.aspx?fn=201506-close06112015.txt
A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.
CASI's turnaround turns eastward; firm seeks to be Celgene of China
Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models
￼A Phase II Study of Oral ENMD-2076 in Advanced Soft Tissue Sarcomas